The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome
Open accessAbstract
Background Intensive low-density lipoprotein cholesterol therapy with ezetimibe/simvastatin in IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) significantly reduced the first primary endpoint (PEP) in patients post-acute coronary syndrome (ACS) compared to placebo/simvastatin.Objectives This analysis tested the hypothesis that total events, including those beyond the first event, would also be reduced with ezetimibe/simvastatin therapy.Methods All PEP events (cardiovascular [CV] death, myocardial infarction [MI], stroke, unstable angina [UA] leading to hospitalization, coronary revascularization ≥30 days post-randomization) during a median 6-year follow-up were analyzed in patients randomized to receive ezetimibe/simvastatin or placebo/simvastatin in IMPROVE-IT. Negative binomial regression was used for the primary analysis.Results Among 18,144 patients, there were 9,545 total PEP events (56% were first events and 44% subsequent events). Total PEP events were significantly reduced by 9% with ezetimibe/simvastatin vs placebo/simvastatin (incidence-rate ratio [RR]: 0.91; 95% confidence interval [CI]: 0.85 to 0.97; p = 0.007), as were the 3 pre-specified secondary composite endpoints and the exploratory composite endpoint of CV death, MI, or stroke (RR: 0.88; 95% CI: 0.81 to 0.96; p = 0.002). The reduction in total events was driven by decreases in total nonfatal MI (RR: 0.87; 95% CI: 0.79 to 0.96; p = 0.004) and total NF stroke (RR: 0.77; 95% CI: 0.65 to 0.93; p = 0.005).Conclusions Lipid-lowering therapy with ezetimibe plus simvastatin improved clinical outcomes. Reductions in total PEP events, driven by reductions in MI and stroke, more than doubled the number of events prevented compared with examining only the first event. These data support continuation of intensive combination lipid-lowering therapy after an initial CV event. (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial [IMPROVE-IT]; NCT00202878).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to their initial events, such patients are at substantial risk for recurrent, potentially fatal events.”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [10]
In the citing paper
“Among 15 480 people randomized to omega-3 fatty acid supplements vs. placebo over a mean follow-up of 7.4 years, there was no significant effect (HR 0.97, 95% CI 0.87-1.08) on serious vascular events [nonfatal MI, non-fatal stroke, transient ischaemic attack (TIA), or vascular death] [329,424-426].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [424]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citationEzetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citationIntensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Regression analysis of multivariate incomplete failure time data by modeling marginal distributions
Wei, L. J., Lin, D. Y., & Weissfeld, L. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478873 · Cited by 1,868
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668 · cited 1×
“(17,18), torcetrapib (19), and dalcetrapib (20).”
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
On the regression analysis of multivariate failure time data
Prentice, R., Williams, B., & Peterson, A. V. (1981) · Biometrika · doi:10.1093/biomet/68.2.373 · Cited by 1,362
de Lemos, J. A., Blazing, M. A., Wiviott, S. D., Lewis, E. F., Fox, K. A. A., White, H. D., Rouleau, J.-L., Pedersen, T. R., Gardner, L. H., Mukherjee, R., et al. (2004) · JAMA · doi:10.1001/jama.292.11.1307 · Cited by 1,333
Self-citationPocock, S., Ariti, C. A., Collier, T. J., & Wang, D. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr352 · Cited by 825
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy
Cannon, C. P., Steinberg, B. A., Murphy, S. A., Mega, J. L., & Braunwald, E. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.070 · Cited by 770
Self-citationCannon, C. P., Giugliano, R. P., Blazing, M. A., Harrington, R. A., Peterson, J. L., Sisk, C. M., Strony, J. T., Musliner, T. A., McCabe, C. H., Veltri, E. P., et al. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.07.023 · Cited by 294
Self-citationMurphy, S. A., Cannon, C. P., Wiviott, S. D., McCabe, C. H., & Braunwald, E. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.005 · Cited by 175
Self-citationChallenges and Opportunities in Quantifying the Quality of Care for Acute Myocardial Infarction
Spertus, J. A., Radford, M. J., Every, N. R., Ellerbeck, E. F., Peterson, E. D., & Krumholz, H. M. (2003) · Circulation · doi:10.1161/01.cir.0000062026.90014.63 · Cited by 111
Blazing, M. A., Giugliano, R. P., Cannon, C. P., Musliner, T. A., Tershakovec, A. M., White, J. A., Reist, C., McCagg, A., Braunwald, E., & Califf, R. M. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.05.004 · Cited by 96
Self-citationCaliff, R. M., Lokhnygina, Y. V., Cannon, C. P., Stepanavage, M. E., McCabe, C. H., Musliner, T. A., Pasternak, R. C., Blazing, M. A., Giugliano, R. P., Harrington, R. A., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.03.004 · Cited by 87
Self-citationTikkanen, M., Szarek, M., Fayyad, R., Holme, I., Cater, N., Faergeman, O., Kastelein, J., Olsson, A., Larsen, M., Lindahl, C., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.08.035 · Cited by 76
LaRosa, J. C., DEEDWANIA, P. C., Shepherd, J., WENGER, N. K., Greten, H., DeMicco, D. A., & Breazna, A. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.09.025 · Cited by 66
Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial
Bakal, J. A., Roe, M. T., Ohman, E. M., Goodman, S. G., Fox, K. A. A., Zheng, Y., Westerhout, C. M., Hochman, J. S., Lokhnygina, Y., Brown, E. B., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu262 · Cited by 59
Self-citationBakal, J. A., Westerhout, C. M., Cantor, W. J., Fernández‐Avilés, F., Welsh, R. C., Fitchett, D., Goodman, S. G., & Armstrong, P. W. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs438 · Cited by 31
Cited by
Sorted by citations
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Aboyans, V., Ricco, J.-B., Bartelink, M.-L. E. L., Björck, M., Brodmann, M., Cohnert, T., Collet, J.-P., Czerny, M., De Carlo, M., Debus, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx095 · Cited by 3,293
2024 ESC Guidelines for the management of peripheral arterial and aortic diseases
Mazzolai, L., Teixidó‐Turà, G., Lanzi, S., Boc, V., Bossone, E., Brodmann, M., Bura-Rivière, A., Backer, J. F. A. D., Déglise, S., Corte, A. D., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae179 · Cited by 1,313
Halliday, A. W., & Bax, J. J. (2018) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2018.03.004 · Cited by 660
Metadata
- Authors
- Murphy, S. A., Cannon, C. P., Blazing, M. A., Giugliano, R. P., White, J. A., Lokhnygina, Y., Reist, C., Im, K., Bohula, E. A., Isaza, D., Lopez-Sendon, J., Dellborg, M., Kher, U., Tershakovec, A. M., & Braunwald, E.
- Affiliations
- Brigham and Women's Hospital (US)
- Duke University (US)
- Institute of Cardiology (CO)
- Hospital Universitario La Paz (ES)
- Sahlgrenska University Hospital (SE)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Murphy, Sabina A.
- ORCID
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 67
- Issue
- 4
- Pages
- 353-361
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2251889296
- Cited by
- 205
- References
- 25
- Citations by year
- 2026: 9 · 2025: 8 · 2024: 13 · 2023: 8 · 2022: 12 · 2021: 26 · 2020: 18 · 2019: 25 · 2018: 21 · 2017: 30 · 2016: 35
- FWCI
- 40.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- GlaxoSmithKline
- Amarin Corporation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- ezetimibe, simvastatin, ezetimibe/simvastatin, acute coronary syndrome, IMPROVE-IT trial, cardiovascular events, LDL cholesterol lowering, lipid-lowering therapy, myocardial infarction, stroke, cardiovascular mortality, secondary prevention, combination therapy, negative binomial regression, incidence rate ratio, coronary revascularization
- MeSH terms
- Ezetimibe, Aged, Anticholesteremic Agents, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Time Factors, United States, Incidence, Survival Rate, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Acute Coronary Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
